Ansari Mudassir, Sadarani Bhakti, Majumdar Anuradha
Department of Pharmacology, Bombay College of Pharmacy, Kalina, Santacruz (E), Mumbai 400098, India.
Saudi Pharm J. 2019 Jan;27(1):71-81. doi: 10.1016/j.jsps.2018.07.021. Epub 2018 Jul 20.
Pterostilbene has a proven chemopreventive effect for colon carcinogenesis but suffers low bioavailability limitations and therefore unable to reach the colonic tissue.
To overcome the issue of low bioavailability, pterostilbene was formulated into an oral colon targeted beads by ionic gelation method using pectin and zinc acetate. Optimization was carried out by 2 factorial design whereby the effect of pectin concentration ( ), zinc acetate concentration ( ) and pterostilbene:pectin ratio ( ) were studied on entrapment efficiency ( ) and drug release till 24 h ( ). The optimized beads were characterized for shape and size, swelling and surface morphology. The optimized beads were uniformly coated with Eudragit S-100 using fluidized bed coater. Optimized coated beads were characterized for drug release till 24 h and surface morphology. Pharmacokinetic and organ distribution study were performed in rats to ascertain the release of pterostilbene in colon.
The optimized formulation comprised of 2% w/v of pectin concentration ( ), 2% w/v of zinc acetate concentration ( ) and 1:4 of pterostilbene:pectin ratio ( ), which showed a satisfactory entrapment efficiency (64.80%) and release (37.88%) till 24 h. The zinc pectinate beads exhibited sphericity, uniform size distribution, adequate swelling and rough surface. The optimized coated beads achieved 15% weight gain, displayed smooth surface and optimum drug release. Pterostilbene from optimized coated beads appeared in the plasma at 14 h and reached the C at 22 h (T), whereas plain pterostilbene exhibited T of 3 h
Thus, larger distribution of pterostilbene was obtained in the colonic tissue compared to stomach and small intestinal tissues. Thus, delayed T and larger distribution of pterostilbene in colonic tissue confirmed the targeting of beads to colon.
紫檀芪对结肠癌发生具有已证实的化学预防作用,但存在生物利用度低的局限性,因此无法到达结肠组织。
为克服生物利用度低的问题,采用离子凝胶法,使用果胶和醋酸锌将紫檀芪制成口服结肠靶向微球。通过二因素设计进行优化,研究果胶浓度( )、醋酸锌浓度( )和紫檀芪与果胶比例( )对包封率( )和24小时内药物释放率( )的影响。对优化后的微球进行形状、大小、溶胀和表面形态表征。使用流化床包衣机将优化后的微球均匀包被Eudragit S - 100。对优化后的包衣微球进行24小时内药物释放和表面形态表征。在大鼠中进行药代动力学和器官分布研究,以确定紫檀芪在结肠中的释放情况。
优化后的制剂包含2% w/v的果胶浓度( )、2% w/v的醋酸锌浓度( )和1:4的紫檀芪与果胶比例( ),其包封率令人满意(64.80%),24小时内的释放率为37.88%。果胶酸锌微球呈现球形、大小分布均匀、溶胀适度且表面粗糙。优化后的包衣微球重量增加了15%,表面光滑且药物释放最佳。优化后的包衣微球中的紫檀芪在14小时出现在血浆中,22小时达到血药浓度峰值(T),而普通紫檀芪的血药浓度峰值时间为3小时。
因此,与胃和小肠组织相比,紫檀芪在结肠组织中的分布更大。因此,紫檀芪在结肠组织中的血药浓度峰值时间延迟和分布更大证实了微球对结肠的靶向性。